<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-229-9-36-43</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2884</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Эндокринные гастроэнтерологические аспекты метаболической дисфункции</article-title><trans-title-group xml:lang="en"><trans-title>Endocrine gastroenterological aspects of metabolic dysfunction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-4275-9645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернядьева</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernyadyeva</surname><given-names>T. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9328-3905</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бонцевич</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bontsevich</surname><given-names>R. A.</given-names></name></name-alternatives><email xlink:type="simple">dr.bontsevich@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9370-4768</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаус</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gaus</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Марийский государственный университет»<country>Россия</country></aff><aff xml:lang="en">Mari State University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО «Марийский государственный университет»; ФГАОУ ВО «Белгородский национальный исследовательский университет»; Казанская государственная медицинская академия - филиал ФГБОУ ДПО РМАНПО<country>Россия</country></aff><aff xml:lang="en">Mari State University; Belgorod National Research University; Kazan State Medical Academy - branch of the Federal State Budgetary Educational Institution of Further Professional Education RMANPO<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Omsk State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>03</month><year>2025</year></pub-date><volume>0</volume><issue>9</issue><fpage>36</fpage><lpage>43</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чернядьева Т.И., Бонцевич Р.А., Гаус О.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Чернядьева Т.И., Бонцевич Р.А., Гаус О.В.</copyright-holder><copyright-holder xml:lang="en">Chernyadyeva T.I., Bontsevich R.A., Gaus O.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2884">https://www.nogr.org/jour/article/view/2884</self-uri><abstract><p>В настоящей публикации представлен обзор современных сведения об аспектах формирования метаболической дисфункции и ее влияния на состояние органов эндокринной системы и желудочно-кишечного тракта. Особое внимание акцентируется на роли ключевых гормонов, таких как инсулин и лептин в регуляции метаболических процессов и функциональной активности органов пищеварения, в частности. Рассматривается вклад метаболической дисфункции в развитие как уже хорошо изученных в этом отношении заболеваний - сахарного диабета 2 типа и ожирения, жировая болезнь печени, желчнокаменная болезнь, а также в отношении отдельных нозологий гастроэнтерологического профиля, в частности синдрома раздраженного кишечника, для которых метаболические нарушения не являются традиционным фактором риска, но определяют особенности клинической картины. Накопленные к настоящему времени данные подчеркивают важность дальнейших исследований в этом направлении для уточнения нашего понимания механизмов, лежащих в основе этих ассоциаций. Результаты данного обзора могут служить основой для разработки новых подходов к диагностике и лечению метаболических нарушений, а также для формирования стратегий по профилактике связанных с ними заболеваний.</p></abstract><trans-abstract xml:lang="en"><p>This review article examines the endocrine gastroenterological aspects of metabolic dysfunction, which is a complex pathological condition that affects metabolism and is accompanied by disturbances in the functioning of the endocrine system. The introduction focuses on key hormones such as insulin and leptin and their roles in regulating metabolism and digestive processes. The consequences of disturbances in the secretion of these hormones, including the development of type 2 diabetes mellitus and obesity, are discussed. The article offers a comprehensive analysis of the relationship between endocrine disruption and gastroenterological problems such as irritable bowel syndrome, highlighting the importance of further research to understand the mechanisms underlying these diseases. The results of this review can serve as the basis for the development of new approaches to the diagnosis and treatment of metabolic disorders, as well as for the formation of strategies for the prevention of associated diseases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Сахарный диабет 2 типа</kwd><kwd>инсулино резистентность</kwd><kwd>метаболический синдром</kwd><kwd>гормоны щитовидной железы</kwd><kwd>жировая болезнь печени</kwd><kwd>ожирение</kwd><kwd>желчнокаменная болезнь</kwd><kwd>синдром раздраженного кишечника</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Type 2 diabetes mellitus</kwd><kwd>insulin resistance</kwd><kwd>metabolic syndrome</kwd><kwd>thyroid hormones</kwd><kwd>fatty liver disease</kwd><kwd>obesity</kwd><kwd>cholelithiasis</kwd><kwd>irritable bowel syndrome</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Semnani S, Roshandel G, Keshtkar A, et al. Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol. 2009;43(9):826-830. doi: 10.1097/MCG.0b013e3181986900 Semnani S, Roshandel G, Keshtkar A, et al. Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol. 2009;43(9):826-830. doi: 10.1097/MCG.0b013e3181986900.</mixed-citation><mixed-citation xml:lang="en">Semnani S, Roshandel G, Keshtkar A, et al. Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol. 2009;43(9):826-830. doi: 10.1097/MCG.0b013e3181986900 Semnani S, Roshandel G, Keshtkar A, et al. Serum leptin levels and irritable bowel syndrome: a new hypothesis. J Clin Gastroenterol. 2009;43(9):826-830. doi: 10.1097/MCG.0b013e3181986900.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Drapkina O.M., Kim O.T. Is brown adipose tissue a new target for obesity therapy? Cardiovascular Therapy and Prevention. 2021;20(5):2860. (In Russ.) doi: 10.15829/1728-8800-2021-2860.@@ Драпкина О.М., Ким О.Т. Бурая жировая ткань - новая мишень борьбы с ожирением? Кардиоваскулярная терапия и профилактика. 2021;20(5):2860. doi: 10.15829/1728-8800-2021-2860.</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Kim O.T. Is brown adipose tissue a new target for obesity therapy? Cardiovascular Therapy and Prevention. 2021;20(5):2860. (In Russ.) doi: 10.15829/1728-8800-2021-2860.@@ Драпкина О.М., Ким О.Т. Бурая жировая ткань - новая мишень борьбы с ожирением? Кардиоваскулярная терапия и профилактика. 2021;20(5):2860. doi: 10.15829/1728-8800-2021-2860.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Maksimov M.L., Filimonova I.M., Shikaleva A.A., Knni Yu.A., Kanunikova E.A., Kanner E.V., Bontsevich R.A. Current issues of diabetes mellitus pharmacotherapy. Clinical pharmacology of hypoglycemic drugs. Textbook for doctors. Kazan, 2023. (in Russ.)@@ Актуальные вопросы фармакотерапии сахарного диабета. Клиническая фармакология сахароснижающих препаратов. Максимов М.Л., Филимонова И.М., Шикалева А.А., Кнни Ю.А., Кануникова Е.А., Каннер Е.В., Бонцевич Р.А. Учебное пособие для врачей / Казань, 2023.</mixed-citation><mixed-citation xml:lang="en">Maksimov M.L., Filimonova I.M., Shikaleva A.A., Knni Yu.A., Kanunikova E.A., Kanner E.V., Bontsevich R.A. Current issues of diabetes mellitus pharmacotherapy. Clinical pharmacology of hypoglycemic drugs. Textbook for doctors. Kazan, 2023. (in Russ.)@@ Актуальные вопросы фармакотерапии сахарного диабета. Клиническая фармакология сахароснижающих препаратов. Максимов М.Л., Филимонова И.М., Шикалева А.А., Кнни Ю.А., Кануникова Е.А., Каннер Е.В., Бонцевич Р.А. Учебное пособие для врачей / Казань, 2023.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mir MM, Mir R, Alghamdi MAA, et al. Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study. J Pers Med. 2022;12(5):735. Published 2022 May 1. doi: 10.3390/jpm12050735.</mixed-citation><mixed-citation xml:lang="en">Mir MM, Mir R, Alghamdi MAA, et al. Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study. J Pers Med. 2022;12(5):735. Published 2022 May 1. doi: 10.3390/jpm12050735.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L, Xuan Y, Zhu Y, et al. Adipocyte secreted NRG4 ameliorates age-associated metabolic dysfunction. Biochem Pharmacol. 2024;225:116327. doi: 10.1016/j.bcp.2024.116327.</mixed-citation><mixed-citation xml:lang="en">Chen L, Xuan Y, Zhu Y, et al. Adipocyte secreted NRG4 ameliorates age-associated metabolic dysfunction. Biochem Pharmacol. 2024;225:116327. doi: 10.1016/j.bcp.2024.116327.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Baldelli S, Aiello G, Mansilla Di Martino E, Campaci D, Muthanna FMS, Lombardo M. The Role of Adipose Tissue and Nutrition in the Regulation of Adiponectin. Nutrients. 2024;16(15):2436. Published 2024 Jul 26. doi: 10.3390/nu16152436.</mixed-citation><mixed-citation xml:lang="en">Baldelli S, Aiello G, Mansilla Di Martino E, Campaci D, Muthanna FMS, Lombardo M. The Role of Adipose Tissue and Nutrition in the Regulation of Adiponectin. Nutrients. 2024;16(15):2436. Published 2024 Jul 26. doi: 10.3390/nu16152436.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Longo L, Marschner RA, de Freitas LBR, et al. Redefining the Role of Ornithine Aspartate and Vitamin E in Metabolic-Dysfunction-Associated Steatotic Liver Disease through Its Biochemical Properties.Int J Mol Sci. 2024;25(13):6839. Published 2024 Jun 21. doi: 10.3390/ijms25136839.</mixed-citation><mixed-citation xml:lang="en">Longo L, Marschner RA, de Freitas LBR, et al. Redefining the Role of Ornithine Aspartate and Vitamin E in Metabolic-Dysfunction-Associated Steatotic Liver Disease through Its Biochemical Properties.Int J Mol Sci. 2024;25(13):6839. Published 2024 Jun 21. doi: 10.3390/ijms25136839.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Patrizio A, Ferrari SM, Elia G, et al. Hypothyroidism and metabolic cardiovascular disease. Front Endocrinol (Lausanne). 2024;15:1408684. Published 2024 Jun 3. doi: 10.3389/fendo.2024.1408684.</mixed-citation><mixed-citation xml:lang="en">Patrizio A, Ferrari SM, Elia G, et al. Hypothyroidism and metabolic cardiovascular disease. Front Endocrinol (Lausanne). 2024;15:1408684. Published 2024 Jun 3. doi: 10.3389/fendo.2024.1408684.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Olanrewaju OA, Asghar R, Makwana S, et al. Thyroid and Its Ripple Effect: Impact on Cardiac Structure, Function, and Outcomes. Cureus. 2024;16(1): e51574. Published 2024 Jan 3. doi: 10.7759/cureus.51574.</mixed-citation><mixed-citation xml:lang="en">Olanrewaju OA, Asghar R, Makwana S, et al. Thyroid and Its Ripple Effect: Impact on Cardiac Structure, Function, and Outcomes. Cureus. 2024;16(1): e51574. Published 2024 Jan 3. doi: 10.7759/cureus.51574.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fiore V, Barucca A, Barraco S, et al. Hypothyroidism in Older Adults: A Narrative Review. Endocr Metab Immune Disord Drug Targets. 2024;24(8):879-884. doi: 10.2174/1871530323666230828110153.</mixed-citation><mixed-citation xml:lang="en">Fiore V, Barucca A, Barraco S, et al. Hypothyroidism in Older Adults: A Narrative Review. Endocr Metab Immune Disord Drug Targets. 2024;24(8):879-884. doi: 10.2174/1871530323666230828110153.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wei Y, Li X, Cui R, Liu J, Wang G. Associations between sensitivity to thyroid hormones and insulin resistance in euthyroid adults with obesity. Front Endocrinol (Lausanne). 2024;15:1366830. Published 2024 Aug 8. doi: 10.3389/fendo.2024.1366830.</mixed-citation><mixed-citation xml:lang="en">Wei Y, Li X, Cui R, Liu J, Wang G. Associations between sensitivity to thyroid hormones and insulin resistance in euthyroid adults with obesity. Front Endocrinol (Lausanne). 2024;15:1366830. Published 2024 Aug 8. doi: 10.3389/fendo.2024.1366830.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jakubiak GK, Pawlas N, Morawiecka-Pietrzak M, Starzak M, Stanek A, Cieślar G. Retrospective Cross-Sectional Study of the Relationship of Thyroid Volume and Function with Anthropometric Measurements, Body Composition Analysis Parameters, and the Diagnosis of Metabolic Syndrome in Euthyroid People Aged 18-65. Medicina (Kaunas). 2024;60(7):1080. Published 2024 Jun 30. doi: 10.3390/medicina60071080.</mixed-citation><mixed-citation xml:lang="en">Jakubiak GK, Pawlas N, Morawiecka-Pietrzak M, Starzak M, Stanek A, Cieślar G. Retrospective Cross-Sectional Study of the Relationship of Thyroid Volume and Function with Anthropometric Measurements, Body Composition Analysis Parameters, and the Diagnosis of Metabolic Syndrome in Euthyroid People Aged 18-65. Medicina (Kaunas). 2024;60(7):1080. Published 2024 Jun 30. doi: 10.3390/medicina60071080.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sagliocchi S, Restolfer F, Cossidente A, Dentice M. The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease. J Basic Clin Physiol Pharmacol. Published online July 19, 2024. doi: 10.1515/jbcpp-2024-0108.</mixed-citation><mixed-citation xml:lang="en">Sagliocchi S, Restolfer F, Cossidente A, Dentice M. The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease. J Basic Clin Physiol Pharmacol. Published online July 19, 2024. doi: 10.1515/jbcpp-2024-0108.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Thakur R, Kumar S, Neeraj RK, Saleem M, Kumar C, Mohan L. Evaluation of the Association between Insulin Resistance and Subclinical Hypothyroidism Using Triglyceride-Glucose Index: a Cross-Sectional Study. Maedica (Bucur). 2024;19(2):255-259. doi: 10.26574/maedica.2024.19.2.255.</mixed-citation><mixed-citation xml:lang="en">Thakur R, Kumar S, Neeraj RK, Saleem M, Kumar C, Mohan L. Evaluation of the Association between Insulin Resistance and Subclinical Hypothyroidism Using Triglyceride-Glucose Index: a Cross-Sectional Study. Maedica (Bucur). 2024;19(2):255-259. doi: 10.26574/maedica.2024.19.2.255.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhai X, Li Y, Teng X, Teng W, Shi X, Shan Z. Relationship Between Serum Thyrotropin Levels and Metabolic Diseases in Older Adults. J Clin Endocrinol Metab. Published online July 2, 2024. doi: 10.1210/clinem/dgae387.</mixed-citation><mixed-citation xml:lang="en">Zhai X, Li Y, Teng X, Teng W, Shi X, Shan Z. Relationship Between Serum Thyrotropin Levels and Metabolic Diseases in Older Adults. J Clin Endocrinol Metab. Published online July 2, 2024. doi: 10.1210/clinem/dgae387.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Roszczyc-Owsiejczuk K, Imierska M, Sokołowska E, et al. shRNA-mediated down-regulation of Acsl1 reverses skeletal muscle insulin resistance in obese C57BL6/J mice. PLoS One. 2024;19(8): e0307802. Published 2024 Aug 23. doi: 10.1371/journal.pone.0307802.</mixed-citation><mixed-citation xml:lang="en">Roszczyc-Owsiejczuk K, Imierska M, Sokołowska E, et al. shRNA-mediated down-regulation of Acsl1 reverses skeletal muscle insulin resistance in obese C57BL6/J mice. PLoS One. 2024;19(8): e0307802. Published 2024 Aug 23. doi: 10.1371/journal.pone.0307802.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Oltmanns KM, Dodt B, Schultes B, et al. Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol. 2006;154(2):325-331. doi: 10.1530/eje.1.02074.</mixed-citation><mixed-citation xml:lang="en">Oltmanns KM, Dodt B, Schultes B, et al. Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol. 2006;154(2):325-331. doi: 10.1530/eje.1.02074.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Piątkowska-Chmiel I, Krawiec P, Ziętara KJ, et al. The Impact of Chronic Stress Related to COVID-19 on Eating Behaviors and the Risk of Obesity in Children and Adolescents. Nutrients. 2023;16(1):54. Published 2023 Dec 23. doi: 10.3390/nu16010054.</mixed-citation><mixed-citation xml:lang="en">Piątkowska-Chmiel I, Krawiec P, Ziętara KJ, et al. The Impact of Chronic Stress Related to COVID-19 on Eating Behaviors and the Risk of Obesity in Children and Adolescents. Nutrients. 2023;16(1):54. Published 2023 Dec 23. doi: 10.3390/nu16010054.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Romaní-Pérez M, Líebana-García R, Flor-Duro A, et al. Obesity and the gut microbiota: implications of neuroendocrine and immune signaling. FEBS J. Published online August 19, 2024. doi: 10.1111/febs.17249.</mixed-citation><mixed-citation xml:lang="en">Romaní-Pérez M, Líebana-García R, Flor-Duro A, et al. Obesity and the gut microbiota: implications of neuroendocrine and immune signaling. FEBS J. Published online August 19, 2024. doi: 10.1111/febs.17249.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Battista F, Bettini S, Verde L, Busetto L, Barrea L, Muscogiuri G. Diet and physical exercise in elderly people with obesity: The state of the art. Eur J Intern Med. Published online August 17, 2024. doi: 10.1016/j.ejim.2024.08.007.</mixed-citation><mixed-citation xml:lang="en">Battista F, Bettini S, Verde L, Busetto L, Barrea L, Muscogiuri G. Diet and physical exercise in elderly people with obesity: The state of the art. Eur J Intern Med. Published online August 17, 2024. doi: 10.1016/j.ejim.2024.08.007.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Akhmedov VA, Gaus OV. Involvement of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-133. (In Russ.) doi: 10.17116/terarkh2017891128-133.@@ Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017. Т. 89. № 1. С. 128-133. doi: 10.17116/terarkh2017891128-133.</mixed-citation><mixed-citation xml:lang="en">Akhmedov VA, Gaus OV. Involvement of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128-133. (In Russ.) doi: 10.17116/terarkh2017891128-133.@@ Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017. Т. 89. № 1. С. 128-133. doi: 10.17116/terarkh2017891128-133.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Aggeletopoulou I, Tsounis EP, Triantos C. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.Int J Mol Sci. 2024;25(9):4901. Published 2024 Apr 30. doi: 10.3390/ijms25094901.</mixed-citation><mixed-citation xml:lang="en">Aggeletopoulou I, Tsounis EP, Triantos C. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.Int J Mol Sci. 2024;25(9):4901. Published 2024 Apr 30. doi: 10.3390/ijms25094901.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Szymala-Pędzik M, Piersiak M, Pachana M, Tomczak W, Sobieszczańska MI, Janocha A. Stłuszczenie wątroby jako czynnik ryzyka chorób sercowo-naczyniowych: analiza retrospektywna danych pacjentów Kliniki Geriatrii Uniwersyteckiego Szpitala Klinicznego we Wrocławiu [Fatty liver as a risk factor for cardiovascular diseases: retrospective analysis of data from patients of the Geriatrics Clinic of University Clinical Hospital in Wrocław]. Med Pr. 2024;75(3):223-231. doi: 10.13075/mp.5893.01510.</mixed-citation><mixed-citation xml:lang="en">Szymala-Pędzik M, Piersiak M, Pachana M, Tomczak W, Sobieszczańska MI, Janocha A. Stłuszczenie wątroby jako czynnik ryzyka chorób sercowo-naczyniowych: analiza retrospektywna danych pacjentów Kliniki Geriatrii Uniwersyteckiego Szpitala Klinicznego we Wrocławiu [Fatty liver as a risk factor for cardiovascular diseases: retrospective analysis of data from patients of the Geriatrics Clinic of University Clinical Hospital in Wrocław]. Med Pr. 2024;75(3):223-231. doi: 10.13075/mp.5893.01510.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lu H, Ban Z, Xiao K, et al. Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease. Adv Sci (Weinh). 2024;11(10): e2308866. doi: 10.1002/advs.202308866.</mixed-citation><mixed-citation xml:lang="en">Lu H, Ban Z, Xiao K, et al. Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease. Adv Sci (Weinh). 2024;11(10): e2308866. doi: 10.1002/advs.202308866.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Serbis A, Polyzos SA, Paschou SA, Siomou E, Kiortsis DN. Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?. Endocrine. 2024;85(3):988-1006. doi: 10.1007/s12020-024-03783-7.</mixed-citation><mixed-citation xml:lang="en">Serbis A, Polyzos SA, Paschou SA, Siomou E, Kiortsis DN. Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?. Endocrine. 2024;85(3):988-1006. doi: 10.1007/s12020-024-03783-7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Volarić M, Šojat D, Majnarić LT, Vučić D. The Association between Functional Dyspepsia and Metabolic Syndrome-The State of the Art.Int J Environ Res Public Health. 2024;21(2):237. Published 2024 Feb 18. doi: 10.3390/ijerph21020237.</mixed-citation><mixed-citation xml:lang="en">Volarić M, Šojat D, Majnarić LT, Vučić D. The Association between Functional Dyspepsia and Metabolic Syndrome-The State of the Art.Int J Environ Res Public Health. 2024;21(2):237. Published 2024 Feb 18. doi: 10.3390/ijerph21020237.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Salgado-Delgado RC, Espinosa-Tanguma R, Valdés Abadía B, Ramírez-Plascencia OD, Escobar C, Saderi N. Feeding during the resting phase causes gastrointestinal tract dysfunction and desynchronization of metabolic and neuronal rhythms in rats. Neurogastroenterol Motil. 2023;35(12): e14687. doi: 10.1111/nmo.14687.</mixed-citation><mixed-citation xml:lang="en">Salgado-Delgado RC, Espinosa-Tanguma R, Valdés Abadía B, Ramírez-Plascencia OD, Escobar C, Saderi N. Feeding during the resting phase causes gastrointestinal tract dysfunction and desynchronization of metabolic and neuronal rhythms in rats. Neurogastroenterol Motil. 2023;35(12): e14687. doi: 10.1111/nmo.14687.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pinelli M, Makdissi S, Scur M. et al. Peroxisomal cholesterol metabolism regulates yap-signaling, which maintains intestinal epithelial barrier function and is altered in Crohn’s disease. Cell Death Dis. 2024;15(7):536. Published 2024 Jul 28. doi: 10.1038/s41419-024-06925-x.</mixed-citation><mixed-citation xml:lang="en">Pinelli M, Makdissi S, Scur M. et al. Peroxisomal cholesterol metabolism regulates yap-signaling, which maintains intestinal epithelial barrier function and is altered in Crohn’s disease. Cell Death Dis. 2024;15(7):536. Published 2024 Jul 28. doi: 10.1038/s41419-024-06925-x.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Casteels P, Kindt S. Diagnosing and managing irritable bowel syndrome with predominant diarrhoea in clinical practice: online survey among gastroenterologists and general practitioners. Acta Gastroenterol Belg. 2024;87(2):229-234. doi: 10.51821/87.2.12586.</mixed-citation><mixed-citation xml:lang="en">Casteels P, Kindt S. Diagnosing and managing irritable bowel syndrome with predominant diarrhoea in clinical practice: online survey among gastroenterologists and general practitioners. Acta Gastroenterol Belg. 2024;87(2):229-234. doi: 10.51821/87.2.12586.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Chlebicz-Wójcik A, Śliżewska K. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules. 2021;11(8):1154. Published 2021 Aug 4. doi: 10.3390/biom11081154.</mixed-citation><mixed-citation xml:lang="en">Chlebicz-Wójcik A, Śliżewska K. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules. 2021;11(8):1154. Published 2021 Aug 4. doi: 10.3390/biom11081154.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012 Aug 14;18(30):4012-8. doi: 10.3748/wjg.v18.i30.4012.</mixed-citation><mixed-citation xml:lang="en">Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012 Aug 14;18(30):4012-8. doi: 10.3748/wjg.v18.i30.4012.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x.</mixed-citation><mixed-citation xml:lang="en">Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x.</mixed-citation><mixed-citation xml:lang="en">Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med. 2012 Aug 3;6(1):16. doi: 10.1186/1751-0759-6-16.</mixed-citation><mixed-citation xml:lang="en">Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med. 2012 Aug 3;6(1):16. doi: 10.1186/1751-0759-6-16.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Wang S, Wang H, et al. Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study. Digestion. Published online July 31, 2024. doi: 10.1159/000540420.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Wang S, Wang H, et al. Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study. Digestion. Published online July 31, 2024. doi: 10.1159/000540420.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Li C, Li J, Zhou Q, Wang C, Hu J, Liu C. Effects of Physical Exercise on the Microbiota in Irritable Bowel Syndrome. Nutrients. 2024;16(16):2657. Published 2024 Aug 11. doi: 10.3390/nu16162657.</mixed-citation><mixed-citation xml:lang="en">Li C, Li J, Zhou Q, Wang C, Hu J, Liu C. Effects of Physical Exercise on the Microbiota in Irritable Bowel Syndrome. Nutrients. 2024;16(16):2657. Published 2024 Aug 11. doi: 10.3390/nu16162657.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham P, Pratap N. Dysbiosis in Irritable Bowel Syndrome. J Assoc Physicians India. 2023;71(9):75-81. doi: 10.59556/japi.71.0353.</mixed-citation><mixed-citation xml:lang="en">Abraham P, Pratap N. Dysbiosis in Irritable Bowel Syndrome. J Assoc Physicians India. 2023;71(9):75-81. doi: 10.59556/japi.71.0353.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Akhmedov V.A., Gaus O.V. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical alphabet. 2019;2(13):52-56. (In Russ.) doi: 10.33667/2078-5631-2019-2-13(388)-52-56.@@ Ахмедов В.А., Гаус О.В. Современные представления о механизмах развития и тактике ведения больных желчнокаменной болезнью, ассоциированной с метаболическим синдромом. Медицинский алфавит. 2019;2(13):52-56. doi: 10.33667/2078-5631-2019-2-13(388)-52-56.</mixed-citation><mixed-citation xml:lang="en">Akhmedov V.A., Gaus O.V. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical alphabet. 2019;2(13):52-56. (In Russ.) doi: 10.33667/2078-5631-2019-2-13(388)-52-56.@@ Ахмедов В.А., Гаус О.В. Современные представления о механизмах развития и тактике ведения больных желчнокаменной болезнью, ассоциированной с метаболическим синдромом. Медицинский алфавит. 2019;2(13):52-56. doi: 10.33667/2078-5631-2019-2-13(388)-52-56.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Gaus O.V., Akhmedov V.A. Clinical, biochemical and immunological features of cholelithiasis associated with metabolic syndrome. Bulletin of the Novosibirsk State University. Series: Biology, clinical medicine. 2013;11(3):125-129. (in Russ.)@@ Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2013. Т. 11. № 3. С. 125-129.</mixed-citation><mixed-citation xml:lang="en">Gaus O.V., Akhmedov V.A. Clinical, biochemical and immunological features of cholelithiasis associated with metabolic syndrome. Bulletin of the Novosibirsk State University. Series: Biology, clinical medicine. 2013;11(3):125-129. (in Russ.)@@ Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2013. Т. 11. № 3. С. 125-129.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Gaus OV, Akhmedov VA. [Evaluation of prognostic factors for the development of cholelithiasis in patients with metabolic syndrome]. Eksp Klin Gastroenterol. 2014;(11):46-50. (in Russ.) PMID: 25842664.@@ Гаус О.В., Ахмедов В.А. Оценка прогностических факторов развития желчнокаменной болезни у лиц с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2014. № 11 (111). С. 46-50.</mixed-citation><mixed-citation xml:lang="en">Gaus OV, Akhmedov VA. [Evaluation of prognostic factors for the development of cholelithiasis in patients with metabolic syndrome]. Eksp Klin Gastroenterol. 2014;(11):46-50. (in Russ.) PMID: 25842664.@@ Гаус О.В., Ахмедов В.А. Оценка прогностических факторов развития желчнокаменной болезни у лиц с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2014. № 11 (111). С. 46-50.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
